Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL10933481

CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.O=P([O-])([O-])F

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.60
SLC22A2 O15244 1/20 0.52
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48
DNM1 Q05193 5/20 0.44
LMNA P02545 1/20 0.41
ESR1 P03372 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CDC25A P30304 1/20 0.41
AGTR1 P30556 1/20 0.41
AKT1 P31749 1/20 0.41
ADRA1A P35348 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL4652889 1.00 SLC22A1 (0.60) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL7800475 1.00 SLC22A1 (0.60) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL19834900 0.92 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL49814 0.92 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
SCHEMBL20543356 0.91 DNM1 (0.52) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL703752 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL31067882 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28547695 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3141779 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28973535 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107004912-B Electrolyte and metal hydride battery 巴斯夫公司 2021-07-30 CN claimed
JP-60152690-A None JP disclosed
EP-4663709-A1 USE OF A MULTIDENTATE LIGAND, INK WITH THE LIGAND, METHOD OF PRODUCING THE INK, PROCESSING THE INK INTO THIN FILM, THE THIN FILM AND ITS USES TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) 2025-12-17 EP disclosed
EP-4205203-B1 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE (\"DMTD\") METAL SALT DERIVATIVES LUBRIZOL CORP (US) 2025-08-06 EP disclosed
US-11967747-B2 Redox flow battery electrolytes with 2,5-dimercapto-1,3,4-thiadiazole (DMTD) and its derivatives THE LUBRIZOL CORPORATION (US) 2024-04-23 US disclosed
US-20230312496-A1 2,5-Dimercapto-1,3,4-Thiadiazole (DMTD) Metal Salt Derivatives LUBRIZOL CORP (US) 2023-10-05 US disclosed
EP-4205203-A1 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE (\"DMTD\") METAL SALT DERIVATIVES The Lubrizol Corporation (US) 2023-07-05 EP disclosed
CN-116210105-A 2, 5-dimercapto-1, 3, 4-thiadiazole ('DMTD') metal salt derivatives 路博润公司 2023-06-02 CN disclosed
US-20220320561-A1 REDOX FLOW BATTERY ELECTROLYTES WITH 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE (DMTD) AND ITS DERIVATIVES LUBRIZOL CORP (US) 2022-10-06 US disclosed
EP-4032136-A1 REDOX FLOW BATTERY ELECTROLYTES WITH 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE (\"DMTD\") AND ITS DERIVATIVES The Lubrizol Corporation (US) 2022-07-27 EP disclosed
CN-114730902-A Redox flow battery electrolytes with 2, 5-dimercapto-1, 3, 4-thiadiazole (\"DMTD\") and derivatives thereof 路博润公司 2022-07-08 CN disclosed
WO-2022046625-A1 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE (\"DMTD\") METAL SALT DERIVATIVES THE LUBRIZOL CORPORATION (US) 2022-03-03 WO disclosed
JP-S60152690-A MANUFACTURE OF POLYPYRROL FILM MATSUSHITA ELECTRIC IND CO LTD 1985-08-10 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312496-A1 2,5-Dimercapto-1,3,4-Thiadiazole (DMTD) Metal Salt Derivatives DIMT1, MPST, TST SLC22A1 2427/4885SLC22A2 2536/4885ALDH1A1 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.